Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $66

Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc.

PTHS

0.00

Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX: PTHS) with a Outperform and raises the price target from $62 to $66.